Depressive Disorder, Major — A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder
Citation(s)
A Six-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of GSK561679 Compared to Placebo in Female Subjects, Diagnosed With Major Depressive Disorder